Literature DB >> 2896779

Eudistomin derivatives, novel phosphodiesterase inhibitors: synthesis and relative activity.

J Kobayashi1, M Taniguchi, T Hino, Y Ohizumi.   

Abstract

The preparations of novel phosphodiesterase inhibitors, 8-acetoxy-5-iodo-6-methoxypyrido[3,4-b]indole, 5,7-dibromo-6-hydroxypyrido[3,4-b]indole, 5,7-dichloro-6-hydroxypyrido[3,4-b]-indole and 8-acetoxy-5-bromo-6-methoxypyrido[3,4-b]indole, are described together with concentrations giving 50% inhibition against cyclic AMP phosphodiesterase, i.e. 3 X 10(-6), 3 X 10(-6), 7 X 10(-6) and 1 X 10(-5) M, respectively. The relative potency of these eudistomin derivatives is discussed in terms of the chemical structures compared with those of other inactive eudistomins and derivatives.

Mesh:

Substances:

Year:  1988        PMID: 2896779     DOI: 10.1111/j.2042-7158.1988.tb05154.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  4,6-Dibromo-3-hydroxycarbazole (an analogue of caffeine-like Ca2+ releaser), a novel type of inhibitor of Ca(2+)-induced Ca2+ release in skeletal muscle sarcoplasmic reticulum.

Authors:  Y Takahashi; K Furukawa; D Kozutsumi; M Ishibashi; J Kobayashi; Y Ohizumi
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

2.  9-Methyl-7-bromoeudistomin D, a potent inducer of calcium release from sarcoplasmic reticulum of skeletal muscle.

Authors:  J Kobayashi; M Ishibashi; U Nagai; Y Ohizumi
Journal:  Experientia       Date:  1989-08-15

3.  Ca2+ release induced by myotoxin alpha, a radio-labellable probe having novel Ca2+ release properties in sarcoplasmic reticulum.

Authors:  K Furukawa; K Funayama; M Ohkura; Y Oshima; A T Tu; Y Ohizumi
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.